Analyst Price Target is $13.50
▲ +27.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Avid Bioservices in the last 3 months. The average price target is $13.50, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 27.00% upside from the last price of $10.63.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Avid Bioservices. This rating has held steady since September 2023, when it changed from a Buy consensus rating.
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
Read More